banner2

MISSION STATEMENT

To improve the lives of patients suffering from rare genetic diseases (“RGD or Orphan Diseases”), and the lives of their families, friends and colleagues. Most patients suffering from Orphan Diseases typically have few, if any, treatment options. Our mission is to bring new biotherapeutics that can improve the lives of these patients via a robust research and development program.

OUR SCIENCE

 

ERAD Therapeutics Inc.

The website is temporarily under construction and will be available soon.

 

banner2

INNOVATIVE SCIENCE

Delivering Protein Therapeutics to the CNS

NEUROMUSCULAR DISEASE

Neuromuscular diseases are a large group of disorders that primarily disrupt the normal functioning of muscles and the nerves that control them. This leads to muscle weakness, impaired movement, and often progressive disability.

Examples of neuromuscular diseases are:

  • Muscular Dystrophy including Duchenne, Becker and many more;
  • Charcot- Marie-Tooth Disease and other neuropathies;
  • Myesthenia-gravis and more

GAUCHER DISEASE

Gaucher Disease is the most common Lysosomal Storage Disease, yet it is still considered an Orphan Disease. Currently affecting over 8,000 American’s, it is a genetic disorder resulting in an enzyme deficiency. Type 1 disease usually results in an enlarged liver, enlarged spleen, anemia and bone disease. Without therapy this significantly impacts both the quality and duration of life. Type 3 disease impacts all of the above as well as causing progressive and ultimately fatal neurological deterioration.

ERAD Therapeutics Inc. Corporate Overview

Expired

An Orphan Drug company with a portfolio of products focusing on Rare Genetic Diseases including Cystic Fibrosis, Lysosomal Storage Diseases, and Neuromuscular Diseases.

Novel, cost-effective gene therapy technology enabling the Company to:

  • Address traditional targeted gene therapy approaches with initial focus on neuromuscular diseases
  • Address a broad range of very rare genetic diseases with a new “gene-agnostic” approach with initial focus on lysosomal storage diseases

Tremendous unmet clinical need

  • Few or no therapeutic options for hundreds of Rare Genetic Diseases.
  • Over 8,000 rare genetic diseases affecting 320 million people and families globally
    • 70% start in childhood
    • Fewer than 5% have approved treatments
  • Neuromuscular diseases have many unmet needs
  • No therapeutic options for the neurological aspects of most rare genetic  diseases
  • Capable of crossing the blood brain barrier

Addressing large Orphan Disease market opportunities

Experienced management team and Board of Directors.